RE:RE:Type C Meeting TimingsType C Meeting -
Type C meeting is any meeting other than a Type A, Type B, Type B (EOP), Type D, or INTERACT meeting regarding the development and review of a product, including meetings to facilitate early consultations on the use of a biomarker as a new surrogate endpoint that has never been previously used as the primary basis for product approval in the proposed context of use.
https://www.fda.gov/media/172311/download
Type B meetings are • Pre-investigational new drug application (pre-IND) meetings.
Type A meeting s are those that are necessary for an otherwise stalled product development program to proceed or to address an important safety issue.